Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells

M Pizzato1, E D Blair, M Fling

  • 1Wohl Virion Centre, Windeyer Institute of Medical Sciences, University College London, UK.

Gene Therapy
|August 30, 2001
PubMed

Insights

Targeting ovarian cancer cells with gene therapy vectors using modified viral envelopes did not improve cell binding or infection. Cellular factors, not added ligands, appear to dominate initial virus-cell interactions for in vivo gene therapy.

Area of Science:

  • Gene therapy vector development
  • Retrovirus biology
  • Cancer cell targeting

Background:

  • Effective in vivo gene therapy requires precise cell-type targeting.
  • Ovarian cancer cells overexpress the alpha folate receptor (alphaFR).
  • Retrovirus vectors are a potential tool for gene delivery.

Purpose of the Study:

  • To engineer retrovirus vectors targeting alphaFR-expressing ovarian cancer cells.
  • To investigate the role of modified viral envelope glycoproteins in cell targeting.
  • To understand virus-cell interactions in the context of targeted gene therapy.

Main Methods:

  • Fusion of single-chain antibody to MLV envelope glycoproteins.
  • Production and analysis of modified retrovirus vectors.
  • Flow cytometry (FACS) and immunofluorescence for studying virus-cell binding.
  • Testing binding to cells with and without alphaFR.

Main Results:

  • Modified viral particles bound to ovarian cancer cells but did not achieve targeted infection.
  • Chimeric and wild-type glycoproteins showed similar binding to targeted and non-targeted cells.
  • Soluble chimeric glycoproteins specifically bound to folate-binding protein (FBP).
  • Env-defective virus particles also showed non-specific binding, indicating cellular factors' role.

Conclusions:

  • Incorporating specific ligands onto viral envelopes does not guarantee enhanced vector binding.
  • Cellular factors within the viral lipid envelope significantly influence initial virus-cell adsorption.
  • Findings impact the interpretation of "targeted" vector studies and future in vivo gene therapy development.

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...